NCT05065645View on ClinicalTrials.gov

Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Inhaled APN01 Developed as Treatment for COVID-19

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 19, 2021

Primary Completion Date

May 27, 2022

Study Completion Date

May 27, 2022

Conditions
Covid19
Interventions
DRUG

Angiotensin Converting Enzyme 2

SAD: single dose; MAD: dosage 2x daily for 7 days

DRUG

Sodium chloride

SAD: single dose; MAD: dosage 2x daily for 7 days

Trial Locations (1)

1090

Medical University of Vienna, Vienna

Sponsors

Lead Sponsor

Apeiron Biologics
All Listed Sponsors
collaborator

Apeiron Respiratory Therapies GmbH

INDUSTRY

lead

Apeiron Biologics

INDUSTRY

NCT05065645 - Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Inhaled APN01 Developed as Treatment for COVID-19 | Biotech Hunter | Biotech Hunter